TIVICAY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
Tivicay is owned by Viiv Hlthcare.
Tivicay contains Dolutegravir Sodium.
Tivicay has a total of 2 drug patents out of which 0 drug patents have expired.
Tivicay was authorised for market use on 12 August, 2013.
Tivicay is available in tablet;oral dosage forms.
The generics of Tivicay are possible to be released after 08 December, 2029.
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
Market Authorisation Date: 12 August, 2013
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage
TIVICAY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic